ALCON INC (ALC)
CH0432492467 - Common Stock
Notable Two Hundred Day Moving Average Cross - ALC
Alcon is Now Oversold (ALC)
Alcon Publishes Agenda for 2024 Annual General Meeting
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
Alcon Non-GAAP EPS of $0.70 beats by $0.02, revenue of $2.33B misses by $10M (NYSE:ALC)
Alcon's Q4 earnings beat expectations with non-GAAP EPS of $0.70, but revenue falls short by $10M.
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
KeyBanc picks Inspire, Integer, ICU Medical as top medtech ideas (NYSE:INSP)
KeyBanc has resumed coverage of nearly a dozen medtech companies, with Inspire (INSP), Integer (ITGR) and ICU Medical (ICUI) as its top investment ideas. Read more here.
Baird bullish on medtech in 2024, but sees weakness in dental market (NASDAQ:DXCM)
Baird expects medtech to outperform the market in 2024, with Alcon, Stryker, Cooper, Boston Sci and Dexcom as top picks, but remains cautious about dental and aesthetics stocks.
Biggest stock movers today: Alcon, Intuitive Surgical, and more (NYSE:ALC)
Stock futures showed modest upward movement during the early hours of Wednesday, yet an air of caution prevailed as Wall Street continued its subdued performanc
Alcon reports positive Phase 3 results for dry eye disease drug (NYSE:ALC)
Alcon (ALC) said two Phase 3 studies for its dry eye disease drug candidate AR-15512 met their primary endpoint. Read more here.
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
ALC Crosses Above Key Moving Average Level
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Baird names top medtech picks for 2024; bullish on Alcon, Axonics (NYSE:ALC)
Baird has chosen Alcon (ALC), Stryker (SYK), The Cooper Companies (COO), Axonics (AXNX), and Boston Scientific (BSX) as top medtech picks for 2024. Read more here.
ALC Crosses Above Key Moving Average Level
Alcon Non-GAAP EPS of $0.66 in-line, revenue of $2.3B misses by $50M (NYSE:ALC)
Alcon reports Q3 results: Non-GAAP EPS in-line, revenue misses, cash from operating activities and free cash flow generate positive results.
Alcon Reports Third Quarter 2023 Results
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
Oversold Conditions For Alcon (ALC)
Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopia
Alcon Breaks Below 200-Day Moving Average - Notable for ALC
Oversold Conditions For Alcon (ALC)
Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...
